Predictive value of KRAS mutations in chemoresistant CRC

被引：30
|
作者：
Lievre, Astrid [2 ]
Laurent-Puig, Pierre [1 ]
机构：
[1] Univ Paris 05, Sch Med, F-75006 Paris, France
[2] INSERM Lab, Paris, France
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2009年 / 6卷 / 06期
关键词：
METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; CETUXIMAB; PANITUMUMAB;
D O I：
10.1038/nrclinonc.2009.69
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
on the basis of the results of KRAS analysis from the CO.17 randomized, controlled, phase III study by Karapetis et al., KRAS mutations have emerged as a valid predictive marker associated with resistance to cetuximab and lack of survival benefit from this anti-EGFR antibody in patients with chemoresistant colorectal cancer.
引用
收藏
页码：306 / 307
页数：3
相关论文
共 50 条
  • [21] The prognostic value of KRAS mutations in patients with colorectal cancer
    Inoue, Yasuhiro
    Saigusa, Susumu
    Iwata, Takashi
    Okugawa, Yoshinaga
    Toiyama, Yuji
    Tanaka, Koji
    Uchida, Keiichi
    Mohri, Yasuhiko
    Kusunoki, Masato
    ONCOLOGY REPORTS, 2012, 28 (05) : 1579 - 1584
  • [22] Prognostic and Predictive Value of KRAS Mutation in NSCLC Response
    Zer, Alona
    Tsao, Ming-Sound
    Shepherd, Frances A.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : E129 - +
  • [23] KRAS Mutations Are Predictive of Outcome in Patients with Pulmonary Sarcomatoid Carcinoma
    Mehrad, Mitra
    Incharoen, Pimpin
    Nikiforova, Marina
    Bittar, Humberto Trejo
    Dacic, Sanja
    LABORATORY INVESTIGATION, 2016, 96 : 476A - 476A
  • [24] KRAS Mutations Are Predictive of Outcome in Patients with Pulmonary Sarcomatoid Carcinoma
    Mehrad, Mitra
    Incharoen, Pimpin
    Nikiforova, Marina
    Bitter, Humberto Trejo
    Dacic, Sanja
    MODERN PATHOLOGY, 2016, 29 : 476A - 476A
  • [25] KRAS Mutations An Old Oncogene Becomes a New Predictive Biomarker
    Riely, Gregory J.
    Ladanyi, Marc
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2008, 10 (06): : 493 - 495
  • [26] Predictive value of FcγRIIa/FcγRIIIa receptors and KRAS mutations in metastatic colorectal cancers treated by cetuximab and irinotecan
    Bibeau, F.
    Crapez, E.
    Di Fiore, F.
    Thezenas, S.
    Ychou, M.
    Lamy, A.
    Blanchard, F.
    Frebourg, T.
    Michel, P.
    Sabourin, J. C.
    Boissiere-Michot, P.
    BULLETIN DU CANCER, 2008, 95 : S48 - S49
  • [27] The predictive value of KRAS and BRAF mutations for outcome in second-line irinotecan monotherapy in metastatic colorectal cancer (mCRC).
    Spindler, K. G.
    Pallisgaard, N.
    Jakobsen, A. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma
    Villaruz, Liza C.
    Socinski, Mark A.
    Cunningham, Diana E.
    Chiosea, Simion I.
    Burns, Timothy F.
    Siegfried, Jill M.
    Dacic, Sanja
    CANCER, 2013, 119 (12) : 2268 - 2274
  • [29] Prognostic value of BRAF and KRAS mutations in colorectal cancer patients
    Murata, Paola
    Stradella, Agostina
    Paez, David
    Tobena, Maria
    Sebio, Ana
    Pare, Laia
    Gonzalez, Alan
    Espinosa, Inigo
    Targarona, Eduardo
    Gich, Ignasi
    Barnadas, Agust
    Baiget, Montserrat
    Martin-Richard, Marta
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [30] PROGNOSTIC VALUE OF BRAF AND KRAS MUTATIONS IN COLORECTAL CANCER PATIENTS
    Murata, E. P.
    Stradella, A.
    Paez, D.
    Tobena Puyal, M.
    Sebio Garcia, A.
    Gonzalez, A.
    Targarona, E.
    Baiget, M.
    Barnadas, A.
    Martin-Richard, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 216 - 216
12345